CN116490180B - 治疗cns病症的方法 - Google Patents

治疗cns病症的方法 Download PDF

Info

Publication number
CN116490180B
CN116490180B CN202280006751.7A CN202280006751A CN116490180B CN 116490180 B CN116490180 B CN 116490180B CN 202280006751 A CN202280006751 A CN 202280006751A CN 116490180 B CN116490180 B CN 116490180B
Authority
CN
China
Prior art keywords
certain embodiments
alkyl
substituted
group
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280006751.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN116490180A (zh
Inventor
梁从新
唐炜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Gaoguang Pharmaceutical Co ltd
Original Assignee
Hangzhou Gaoguang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Gaoguang Pharmaceutical Co ltd filed Critical Hangzhou Gaoguang Pharmaceutical Co ltd
Priority to CN202410217414.3A priority Critical patent/CN118059096A/zh
Publication of CN116490180A publication Critical patent/CN116490180A/zh
Application granted granted Critical
Publication of CN116490180B publication Critical patent/CN116490180B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280006751.7A 2021-09-13 2022-08-22 治疗cns病症的方法 Active CN116490180B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410217414.3A CN118059096A (zh) 2021-09-13 2022-08-22 治疗cns病症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021110699900 2021-09-13
CN202111069990 2021-09-13
PCT/CN2022/113807 WO2023035913A1 (en) 2021-09-13 2022-08-22 Methods of treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410217414.3A Division CN118059096A (zh) 2021-09-13 2022-08-22 治疗cns病症的方法

Publications (2)

Publication Number Publication Date
CN116490180A CN116490180A (zh) 2023-07-25
CN116490180B true CN116490180B (zh) 2024-03-22

Family

ID=85506085

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280006751.7A Active CN116490180B (zh) 2021-09-13 2022-08-22 治疗cns病症的方法
CN202410217414.3A Pending CN118059096A (zh) 2021-09-13 2022-08-22 治疗cns病症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410217414.3A Pending CN118059096A (zh) 2021-09-13 2022-08-22 治疗cns病症的方法

Country Status (8)

Country Link
US (1) US20250032465A1 (https=)
EP (1) EP4419101A4 (https=)
JP (1) JP2024543198A (https=)
CN (2) CN116490180B (https=)
AU (1) AU2022342095A1 (https=)
CA (1) CA3239065A1 (https=)
IL (1) IL313097A (https=)
WO (1) WO2023035913A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244611A1 (en) * 2022-06-13 2023-12-21 Emory University Uses of jak inhibitors in the management of inflammation-associated depression and central nervous system (cns) pathologies
CN120152713A (zh) * 2022-07-29 2025-06-13 昂胜医疗科技公司 三环芳基衍生物及其组合物和方法
WO2025224600A1 (en) 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
WO2025248468A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
WO2026032213A1 (zh) * 2024-08-08 2026-02-12 普罗思特(南京)生物科技有限公司 取代的三环衍生物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366994A (zh) * 2016-10-03 2018-08-03 梁从新 新型Jak1选择性抑制剂及其用途
WO2020244349A1 (zh) * 2019-06-06 2020-12-10 广州高瓴制药有限公司 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2473579B (en) * 2008-06-30 2013-01-30 Biotechnology Res Corp Ltd Stat3 and TYK2 as drug targets for neurodegenerative diseases
CN105636962B (zh) * 2013-10-15 2017-10-13 靳博涵 新型化合物、用途及其制备方法
BR112021024533A2 (pt) 2019-06-06 2022-01-18 Highlightll Pharmaceutical Hainan Co Ltd Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108366994A (zh) * 2016-10-03 2018-08-03 梁从新 新型Jak1选择性抑制剂及其用途
WO2020244349A1 (zh) * 2019-06-06 2020-12-10 广州高瓴制药有限公司 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物

Also Published As

Publication number Publication date
JP2024543198A (ja) 2024-11-19
AU2022342095A1 (en) 2024-06-27
US20250032465A1 (en) 2025-01-30
CN118059096A (zh) 2024-05-24
EP4419101A1 (en) 2024-08-28
CA3239065A1 (en) 2023-03-16
IL313097A (en) 2024-07-01
EP4419101A4 (en) 2025-09-03
WO2023035913A1 (en) 2023-03-16
CN116490180A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
CN116490180B (zh) 治疗cns病症的方法
EP3347018B1 (en) Inhibitors of cyclin-dependent kinases
CN113557017B (zh) 细胞周期蛋白依赖性激酶7的抑制剂及其用途
AU2015292827A1 (en) Macrocyclic kinase inhibitors and uses thereof
AU2016319785A1 (en) Acetamide thienotriazoldiazepines and uses thereof
AU2020319005A1 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
AU2015335788A1 (en) Thiazolyl-containing compounds for treating proliferative diseases
HK40094824B (zh) 治疗cns病症的方法
HK40094824A (zh) 治疗cns病症的方法
HK40108558A (zh) 治疗cns病症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094824

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant